Drugs for Treatment of Constipation Market to Touch USD 15.72 billion by 2030; Surging Applications of Methylcellulose Fiber and Proliferating Applications of Opioid Receptor Antagonists, poised to Facilitate Market Growth

Drugs for Treatment of Constipation market size is estimated to reach $15.72 billion by 2030, growing at a CAGR of 6% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Drugs for Treatment of Constipation Market – By Therapeutic (Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C Agonists, 5-HT4 Receptor Agonists and Others), By Disease Type (Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome with Constipation (IBS-C) and Opioid-Induced Constipation (OIC)), By Prescription Type (Prescribed Drugs, Over-the-Counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”.  The growth of the Drugs for Treatment of Constipation Market is fuelled by the expanding count of elderly patients, surging applications of methylcellulose fiber and proliferating applications of opioid receptor antagonists. 

North America held the largest Drugs for Treatment of Constipation Industry Market share with 40% of the overall market in 2030. The growth of this region is owing to the increasing predominance of chronic constipation that requires the application of lactulose and linaclotide in the North American region. The burgeoning financing in healthcare is further propelling the growth of the Constipation Treatment Industry, thereby contributing to the Constipation Treatment Industry Outlook in the North American region. 

Methylcellulose (Citrucel) comes under the category of bulk-forming laxatives. It boosts the bulk of stools leading to enhanced intestinal motility and regulating bowel activities. It is utilized as an adjunct to diet and additional therapies in the treatment of constipation and to restore & maintain bowel regularity. For children aged 6 to 11 years, one caplet of Citrucel tablet, as needed up to six times per day, may be recommended for the treatment of constipation. The maximum dose per day is 6 caplets. The surging applications of Methylcellulose Fiber are therefore fuelling the growth of the Drugs for Treatment of Constipation Industry Market during the forecast period 2024-2030.

Opioid antagonists not only have entrenched indications in the reversal of life-alarming opioid toxicity but also hold significant promise for additional applications in palliative care practice, specifically in handling of opioid-induced constipation (OIC). Currently, numerous opioid receptor antagonists have been presented in the treatment of OIC. Methylnaltrexone (MNTX) is designated for patients with OIC who are not agreeable to therapy with oral laxatives. In clinical trials, the efficiency of MNTX assessed as its ability to induce a spontaneous bowel movement is 50%-60% of treated patients. The proliferating applications of Opioid Receptor Antagonists are therefore driving the growth of the Constipation Treatment Industry, thereby contributing to the Constipation Treatment Industry Outlook during the forecast period 2024-2030.

• In January 2022, Takeda stressed a strategy for conveying sustainable development over the next ten years at the 40th Annual J.P. Morgan Healthcare Conference. Takeda’s powerful pipeline includes nearly 40 diverse, clinical-stage assets. They would offer the promise of a considerable count of regulatory approvals.

• In May 2023, Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases.

Key companies profiled in the Drugs for Treatment of Constipation Market are Takeda Pharmaceutical Company Ltd., Ironwood Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Abbott Laboratories, AstraZeneca Plc, Cosmo Pharmaceuticals NV, Sanofi S.A., Bayer AG, AbbVie Inc., Pfizer Inc.